TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Fred Hutchinson Cancer Center